RNS Number : 6560F
23 March 2022
("GENinCode" or the "Company")
Collaboration with Indiana University School of Medicine
Study for testing Cardio inCode-SCORE for the risk of onset of
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics
company focused on the prevention of cardiovascular disease,
announces its collaboration with the Indiana University School of
Medicine ("IU"). IU is the largest medical school in the US and
will undertake a 'Proof of Concept' study using Cardio inCode-SCORE
for the risk assessment of patients for onset of atherosclerotic
cardiovascular disease ("ASCVD "). ASCVD accounts for over 85% of
all cardiovascular disease deaths and is the leading cause of
morbidity and mortality in the US and globally.
According to the Centres for Disease Control and Prevention
("CDC"), cardiovascular disease ("CVD") is the number one cause of
death in the United States and the decades--long trend towards
lower cardiovascular mortality rates has begun to reverse, with an
increase in total mortality during recent years:
CVD disproportionately affects people of lower socioeconomic
status, and those of non--white ethnicity. Early identification of
subclinical disease in the population can lead to better primary
prevention of heart attack and stroke. Current American College of
Cardiology ("ACC") guidelines call for risk stratification using
validated instruments, such as the US National Heart Lung and Blood
Institute ("NHLBI") pooled risk cohort equation, drawing on
clinical parameters readily available such as blood pressure and
cholesterol levels. In addition, the guidelines endorse the use of
"risk enhancing factors" such as the Coronary Artery Calcium
("CAC") score, undertaken using computerised tomography ("CT")
imaging of the coronary arteries.
Whilst acknowledging family history as a risk factor, current
guidelines have not yet incorporated the potential of genetic risk
assessment in the prediction of ASCVD. Cardio inCode-SCORE provides
an opportunity to apply advanced polygenic testing to improve
patient risk assessment and prognosis, in a widely available form
and at reduced cost compared with other test modalities.
The primary aim of the IU study is to evaluate the association
between the Cardio inCode-SCORE genetic risk score ("GRS") and the
presence of subclinical coronary atherosclerosis evaluated by
CVD is a broad disease classification which encompasses
conditions such as coronary artery disease (causing angina, heart
attacks, heart failure), cerebrovascular disease (causing stroke,
and some dementia), peripheral vascular disease (causing limb
ischemia, and some chronic kidney disease) and venous
thromboembolism. CVD is the leading cause of death and disability
worldwide accounting for one in every four deaths in the United
States. According to the US National Institutes of Health ("NIH"),
by 2030, the global cost of CVD is set to rise to US$1,044 billion,
from approximately US$863 billion in 2010, and is both a major
health issue and global economic burden.
GENinCode has a vision to assist clinicians and inform patients
about cardiovascular risk, and to improve public health using the
predictive capability of genomics. High genetic risk patients are
assisted in making lifestyle choices and can receive targeted
treatment to improve outcomes. Over the past 15 years , GENinCode
has made a substantial investment in its research, bioinformatic
data, technology, and product development to assess disease risk,
in order to help clinicians and patients prevent the onset of
Matthew Walls, CEO, GENinCode said: "We are delighted to work
with the IU School of Medicine and to introduce Cardio inCode-SCORE
to the IU health community. The IU study follows on from our
recently published US clinical performance studies showing the
substantive predictive capability of the Cardio inCode-SCORE
product for the risk assessment of patients for the onset of
cardiovascular disease. We look forward to working closely with the
IU team to successfully deliver the programme ."
Richard Kovacs MD, Q.E. and Sally Russell Professor of
Cardiology in the Division of Cardiovascular
Disease at IU School of Medicine commented: "The GENinCode and
IU collaboration offers the potential to improve the prediction of
ASCVD and better assess patient risk of future CVD events. GRS's
provide an opportunity to enhance assessment of risk based on
'classic' CVD risk factors and help physicians identify patients at
higher inherited genetic risk, thereby targeting improved treatment
and reduction in future CVD events. IU welcomes this approach and
we look forward to working with Cardio inCode-SCORE to advance
preventative CVD care."
For more information visit www.genincode.com
GENinCode Plc www.genincode.com or via Walbrook
Matthew Walls, CEO
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
and Joint Broker)
Alex Price / Ben Maddison /
Cenkos Securities Plc (Joint Tel: +44 (0)20 7397 8900
Dale Bellis / Michael Johnson
Walbrook PR Limited Tel: 020 7933 8780 or
Anna Dunphy / Paul McManus / Louis firstname.lastname@example.org
GENinCode Plc is a UK based company specializing in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through
GENinCode S.L.U, and in the United States through GENinCode U.S.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical algorithms and bioinformatics to provide advanced patient
risk assessment to predict disease onset.
About Indiana University School of Medicine
IU School of Medicine is the largest medical school in the
United States. Comprised of five basic science departments and 20
clinical departments, IU School of Medicine offers exceptional
training for students wishing to pursue a medical degree. With the
Class of 2020, the school implemented a new medical education
curriculum that better reflects the modern U.S. health care
environment and delivery models, readying students to practice
medicine in a team-based, interdisciplinary setting.
-- Statewide medical education centers on six core competencies.
-- Access to diverse patient populations reflects true state of care today.
-- Updates align innovations in medical science and education.
-- Global outreach, clinical education programs foster active learning.
-- Collaborative teaching and learning forges interprofessional bonds.
-- Academic advising and career counseling support and guide students.
About Cardiovascular Disease (CVD or Heart Disease) in the US:
Centres for Disease Control Prevention information (CDC)
-- Heart disease is the leading cause of death for men, women,
and people of most racial and ethnic groups in the United
-- One person dies every 36 seconds in the United States from cardiovascular disease.
-- About 659,000 people in the United States die from heart
disease each year-that's 1 in every 4 deaths .
-- Heart disease costs the United States about $363 billion each
year from 2016 to 2017.(2) This includes the cost of health care
services, medicines, and lost productivity due to death.
Coronary Artery Disease/Coronary Heart Disease
-- Coronary heart disease is the most common type of heart
disease, killing 360,900 people in 2019.
-- About 18.2 million adults age 20 and older have CAD (about 6.7%).
-- About 2 in 10 deaths from CAD happen in adults less than 65 years old.
-- In the United States, someone has a heart attack every 40 seconds.
-- Every year, about 805,000 people in the United States have a heart attack. Of these,
o 605,000 are a first heart attack
o 200,000 happen to people who have already had a heart
o About 1 in 5 heart attacks is silent -the damage is done, but
the person is not aware of it.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
March 23, 2022 03:00 ET (07:00 GMT)
Historical Stock Chart
From Sep 2022 to Oct 2022
Historical Stock Chart
From Oct 2021 to Oct 2022